Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis

Fig. 1

Patients reporting no enthesitis (a) and no dactylitis (b) at week 24. Integrated analysis set with baseline enthesitis and dactylitis are shown as the percentages of responders (95% CI, NRI). *P vs PBO < 0.05; **P vs PBO < 0.001. Abbreviations: Achill tend insert, Achilles tendon insertion; CI, confidence interval; IXEQ2W, ixekizumab 80 mg every 2 weeks; IXEQ4W, ixekizumab 80 mg every 4 weeks; Lat epicond, lateral epicondyle; LEI, Leeds Enthesitis Index; LDI-B, Leeds Dactylitis Index-Basic; Med fem cond, medial femoral condyle; NRI, nonresponder imputation; PBO, placebo

Back to article page
\